Stock ROIV ROIVANT SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
10.48 USD -0.76% Intraday chart for Roivant Sciences Ltd. -0.85% -6.68%
Jul. 01 Roivant Sciences Ltd.(NasdaqGS:ROIV) dropped from Russell 2500 Growth Index CI
Jul. 01 Roivant Sciences Ltd.(NasdaqGS:ROIV) dropped from Russell 3000E Growth Index CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Roivant Sciences Ltd.(NasdaqGS:ROIV) dropped from Russell 2500 Growth Index
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) dropped from Russell 3000E Growth Index
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) dropped from Russell 3000 Growth Index
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to Russell 1000 Value-Defensive Index
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) dropped from Russell Small Cap Comp Growth Index
CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) dropped from Russell 1000 Growth Index
CI
Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:40 AM
Transcript : Roivant Sciences Ltd. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:30 AM
Roivant Sciences Ltd. Reports Earnings Results for the Full Year Ended March 31, 2024
CI
Roivant Sciences : 4Q2023 Earnings Call Presentation
PU
Transcript : Roivant Sciences Ltd., Q4 2024 Earnings Call, May 30, 2024
Roivant Sciences' Fiscal Q4 Net Loss Widens, Revenue Rises
MT
Futures Decline Pre-Bell as Traders Await Key Economic Reports; Asia Down, Europe Rises
MT
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
GL
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
AQ
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
CI
Transcript : Roivant Sciences Ltd. Presents at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, May-20-2024 09:00 AM
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
GL
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit
MT
Moderna Suffers Setback in Lawsuit by Arbutus
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROIV Stock
  4. News Roivant Sciences Ltd.